HeartBeam Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care, has received U.S. Food and Drug Administration Breakthrough Device Designation for its HeartBeam System as a tool for assessing potential heart attacks at home. The designation, granted within 30 days of the company's request, ahead of the agency's 60-day statutory review period, recognizes the potential of HeartBeam's 3D ECG technology to enable physicians to evaluate signs of a possible heart attack when symptoms begin, wherever the patient may be. This matters because time is muscle in cardiac care: the sooner a heart attack is identified, the faster treatment can begin, potentially saving heart muscle and lives.
The FDA's Breakthrough Device Designation provides prioritized FDA review and more interactive communication as HeartBeam advances its heart attack assessment program. Importantly, the designation is a prerequisite for certain expedited Medicare coverage pathways, which could accelerate patient access and reimbursement if the technology gains clearance for this indication. The company expects to seek FDA alignment on the design of a multicenter pivotal study in the coming months and anticipates beginning patient enrollment shortly thereafter. If successful, the study is intended to support a future submission to expand the HeartBeam System indications to include heart attack assessment.
HeartBeam's technology platform is designed to be a cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing them into a 12-lead ECG. This portability could allow for actionable heart intelligence outside of medical facilities, redefining cardiac health management. The company's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and for its 12-lead ECG synthesis software in December 2025, and it holds over 20 issued patents related to technology enablement.
The Breakthrough Device Designation also signals to investors and the medical community that HeartBeam's approach is considered promising for a life-threatening condition. For more details, see the full press release at https://nnw.fm/FxKxf and the company's newsroom at https://nnw.fm/BEAT. The announcement was distributed by NetworkNewsWire, a specialized communications platform that is part of the Dynamic Brand Portfolio at IBN, which offers services including InvestorWire for wire distribution and editorial syndication to 5,000+ outlets.
